Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

What this study is testing ClinicalTrials.gov NCT07309094 ↗

Description as written by the study sponsor.

Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in which the patient requires dialysis. Several risk factors are reported for CKD, such as diabetes mellitus, obesity and hypertension. One of the most increasingly recognized risk factors is the fat tissue malfunction, known as adiposopathy. The accumulation of fat tissue around the organs in conditions of obesity or diabetes accelerates the production of pro-inflammatory factors that may worsen the kidney and heart damage. New antidiabetic medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RA), have proven beneficial effects on the kidney and heart due to several mechanisms, including anti-inflammatory actions and a potential action on the fat tissue. The aim of this study is to assess the link between adiposopathy and CKD, by investigating the changes in adiposopathy measures throughout treatment with GLP-1RA to a sample of patients with CKD.

Treatments tested

• GLP-1 receptor agonist also known as semaglutide, liraglutide, dulaglutide, exenatide Drug

  Semaglutide: weekly subcutaneous administration, starting dose 0.25mg, maintenance dose 1mg

• SGLT2 inhibitor also known as dapagliflozin, empagliflozin, canagliflozin Drug

  dapagliflozin: oral administration from 5 to 10mg/day

• Tirzepatide Drug

  subcutaneous injection: starting dose 2.5 mg, maintenance 5mg (weekly administration)

• Other drugs also known as ARBs, ACE inhibitors, Metformin, DPP4i, non steroidal mineralocorticoid receptor agonists Drug

  Patients not under SGLT2i or GLP-1RA influence, but receiving other treatments which are part of CKD standard care: mineralocorticoid receptor agonists, metformin, ACE inhibitors, ARBs...